Atorvastatin + Placebo

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus

Trial Timeline

Mar 1, 2003 → Oct 1, 2004

NCT ID

NCT00640549

About Atorvastatin + Placebo

Atorvastatin + Placebo is a approved stage product being developed by Pfizer for Hyperlipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00640549. Target conditions include Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus.

What happened to similar drugs?

7 of 20 similar drugs in Hyperlipidemia were approved

Approved (7) Terminated (1) Active (12)

✅Diet+pravastatinDaiichi SankyoApproved

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved

✅Rosuvastatin (Crestor)AstraZenecaApproved

✅simvastatin + EzetimibeMerckApproved

✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved

✅atorvastatin + atorvastatin + atorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00756886	Pre-clinical	Completed	Sep 1, 2008	May 1, 2011	Arrhythmia
NCT00579098	Approved	Completed	Dec 1, 2007	Dec 1, 2011	Atrial Fibrillation
NCT00517257	Phase 3	UNKNOWN	Aug 1, 2007	Sep 1, 2009	Retinal Vein Occlusion
NCT00481364	Phase 3	Completed	Nov 1, 2006	Dec 1, 2008	Vascular Calcification
NCT01072097	Pre-clinical	Completed	Sep 1, 2006	Jan 1, 2011	Polycystic Ovary Syndrome
NCT00252967	Phase 3	Terminated	Oct 1, 2005	Oct 1, 2009	Atrial Fibrillation
NCT00233480	Approved	Completed	Aug 1, 2005	Feb 1, 2009	Heart Failure, Congestive
NCT00587379	Pre-clinical	Withdrawn	Jun 1, 2004	May 1, 2008	Endothelial Dysfunction
NCT00640549	Approved	Terminated	Mar 1, 2003	Oct 1, 2004	Hyperlipidemia

Competing Products

20 competing products in Hyperlipidemia

See all competitors

Product	Company	Stage	Hype Score
DRL-17822 or placebo	Dr. Reddy's Laboratories	Phase 2	32
VK2809 + Placebo	Viking Therapeutics	Phase 2	32
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo	Yuhan	Phase 3	40
Diet+pravastatin	Daiichi Sankyo	Approved	43
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
Minute Maid Heart Wise orange juice + Welchol	Daiichi Sankyo	Approved	43
Pravafen + Pravastatin + Fenofibrate	Shionogi	Phase 3	40
Evacetrapib + Atorvastatin + Ezetimibe + Placebo	Eli Lilly	Phase 3	32
exenatide	Eli Lilly	Pre-clinical	26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC	Eli Lilly	Phase 1	29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209	Jiangsu Hengrui Medicine	Phase 1	29
SHR-1209 + Placebo	Jiangsu Hengrui Medicine	Phase 1/2	32
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 2	35
Rosuvastatin (Crestor)	AstraZeneca	Approved	39
simvastatin + Ezetimibe	Merck	Approved	43
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	40
simvastatin 20 mg/ezetimibe	Merck	Phase 2/3	38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin	Merck	Phase 3	47